Structure/Class |
|
Pharmacodynamics |
- NSAIDs function by inhibiting COX and therefore leading to less prostaglandin synthesis.
- Aspirin irreversibly inhibits COX.
- Non-COX selective NSAIDs reversibly inhibit COX.
- Selective COX-2 NSAIDs will not have anti-platelet function.
- Comparative effects as follows:
- COX-2 drugs have less GI effects, but increased oedema and HTN.
- NSAIDs overall will decrease the sensitivity of blood vessels to bradykinin and histamine, affect lymphokine production from T-cells and reverse vasodilation associated with inflammation.
- All NSAIDs will have analgesic/anti-pyretic and anti-inflammatory effects.
- All NSAIDs (except the COX-2 specific ones) have anti-platelet activity.
- Some NSAIDs (including aspirin) are thought to reduce colon cancer risk.
- With respect to GI effects:
- Ibuprofen thought to have the least GIT effects.
- Piroxicam has 9x the GIT effects.
- Aspirin has double the GIT effects.
- Indomethacin may cause pancreatitis.
|
Absorption/administration |
- PO. Some may be given IV or IM.
- Importantly, food does not lower its bioavailability.
|
Distribution |
- All are weak acids and therefore absorbed well in the GIT.
- They are all highly protein bound (>98% to albumin).
- They are all found in high concentration in synovial fluids.
|
Metabolism |
- Hepatic, by CYP systems and phase 2 reactions.
|
Excretion |
- Renal
|
Indications |
|
Contraindications |
|
Special precautions |
|
Interactions |
- Lithium – may increase lithium levels secondary to reducing renal blood flow.
- Increased risk of bleeding with other anticoagulants.
|
Adverse events |
- Toxic effects
- Mainly GIT (gastritis, nausea/vomiting, ulcers and bleeding)
- Renal – AKI (probably secondary to altered renal blood flow due to reduced prostaglandin synthesis)
- Hepatic – abnormal LFTs and rarely, hepatic failure.
- CNS – tinnitus, dizziness and headaches.
|
Dosing/administration |
|
Toxicology |
- Good supportive care
|
Withdrawal syndrome |
|
Special notes |
|